Genetic modification of donor animals
A primary strategy to reduce immune rejection is genetic engineering of donor pigs to remove or mask molecular targets that trigger human immune responses. Researchers have deleted the alpha-galactosyl epitope by targeting the GGTA1 gene and altered other carbohydrate antigens such as CMAH and B4GALNT2 to lower hyperacute and acute antibody-mediated rejection. George M. Church Harvard Medical School and colleagues used CRISPR-based approaches to inactivate porcine endogenous retroviruses, addressing infectious risk while enabling multiple simultaneous edits. These edits are complemented by insertion of human regulatory genes for complement and coagulation control to make the graft less proinflammatory.
Complement and coagulation control
Integration of human complement regulatory proteins such as CD46 CD55 and CD59 and expression of human thromboregulatory molecules aim to prevent complement activation and microvascular thrombosis that commonly destroy xenografts. complement regulation and coagulation modulation reduce early graft injury and create a more compatible endothelial phenotype. Bartley P. Griffith University of Maryland School of Medicine and teams involved in clinical attempts combine such genetic strategies with intensive perioperative management to address immediate rejection mechanisms.
Modulating the recipient immune system
On the recipient side, modern regimens emphasize costimulation blockade and targeted immunosuppression rather than high-dose broad suppression alone. Antibodies against CD40 or its ligand interrupt B cell and T cell activation pathways driving xenograft-specific responses. Approaches that induce durable immune tolerance include mixed hematopoietic chimerism thymic transplantation and adoptive transfer of regulatory T cells, each intended to retrain the immune system to accept donor antigens with less chronic medication. David K.C. Cooper University of Alabama at Birmingham has reviewed how combinations of gene-edited donors and refined immunomodulation improve outcomes in preclinical models.
Risks, cultural and environmental nuances
Infectious risk remains a critical concern and is actively studied by transplant infectious disease experts such as Jay A. Fishman Massachusetts General Hospital who emphasize surveillance for zoonotic agents and robust screening of donor herds. Cultural and religious perspectives on using pig organs influence acceptability in many regions, requiring engagement with communities and ethicists. Environmental and territorial considerations include responsible breeding practices and biosecurity to prevent pathogen spillover. Together, multilayered engineering of the donor, targeted recipient therapies, and rigorous infection control form the current roadmap for reducing immune rejection in xenotransplantation.